WEST DES MOINES, IA--(Marketwired - Aug 24, 2015) - Spotlight Innovation Inc. (
Dr. Paul Reid, President of Celtic Biotech, said "We are gratified that Phase I Part 1 of the study was completed. Our Contract Research Organization for the Paris, France-based study, ImmunoClin Ltd., conducted the innovative trial design. The study went as planned and was monitored to international regulatory standards of good clinical practice. The clinical data is now being assembled and organized in preparation for analysis by a scientific review committee as mandated by the protocol. We expect results from the review committee to be available on or about November 2015. In the expectation that the scientific review will be successful, we have begun taking the steps necessary to initiate Part 2 of the study, which we anticipate will begin in January 2016."
"The completion of this clinical trial phase is a significant milestone," said Cris Grunewald, President and CEO of Spotlight Innovation. "Moving Crotoxin successfully through the clinical trial process is a high priority. It is our hope that these clinical trials will eventually lead to significant help for people with lung, breast and skin cancers. The American Cancer Society estimates that over two hundred thousand Americans alone will die from these cancers in 2015."
About Spotlight Innovation Inc.
Spotlight Innovation Inc. (
About Celtic Biotech Iowa, Inc.
Celtic Biotech Iowa, Inc., a subsidiary of Spotlight Innovation Inc., is developing novel, clinical trial-phase products for the treatment of cancers and pain in humans. Derived from naturally specialized receptor-binding proteins, these products have the potential to reduce treatment costs, increase survivability, and improve the quality-of life for cancer patients. Additional information available at www.celticbiotech.com.
About the ImmunoClin Corporation
ImmunoClin Corporation (
Forward Looking Statements
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
Contact Information:
Press Contact
Rene Erickson
Spotlight Innovation Inc.
1-515-274-9087
corpcomm@spotlightinnovation.com
Investor Contact
Rudy Barrio
DresnerAllenCaron
1-212-691-8087
r.barrio@allencaron.com
Photographs of Crotalus durissus are available for the media upon request from DresnerAllenCaron by contacting Rudy Barrio at 212-691-8087.